- Talaporfin
-
Talaporfin Systematic (IUPAC) name N-{[(2S,3S)-7-carboxy-3-(2-carboxyethyl)-12-ethyl-2,8,13,18-tetramethyl-17-vinyl-2,3-dihydroporphyrin-5-yl]acetyl}-L-aspartic acid Clinical data AHFS/Drugs.com International Drug Names Pregnancy cat. ? Legal status ℞ Prescription only Routes IV Identifiers CAS number 110230-98-3
220201-34-3 (sodium salt)ATC code None PubChem CID 5486799 UNII P4ROX5ELT2 Chemical data Formula C38H41N5O9 Mol. mass 711.76 g/mol SMILES eMolecules & PubChem (what is this?) (verify) Talaporfin (INN, also known as aspartyl chlorin, mono-L-aspartyl chlorine e6, NPe6, or LS11) is a photosensitizer used in photodynamic therapy (PDT).
It absorbs red light at 664nm normally provided by a laser tuned to this wavelength.[1]
It was approved in Japan (in 2004) for PDT of lung cancer and marketed as Laserphyrin.[2]
It is trademarked as Aptocine by Light Sciences Oncology.[3]
References
- ^ http://journals.lww.com/jto/Fulltext/2006/06000/Photodynamic_Therapy__PDT__for_Lung_Cancers.18.aspx "Photodynamic Therapy (PDT) for Lung Cancers" 2006
- ^ http://meeting.ascopubs.org/cgi/content/abstract/24/18_suppl/7229 "Photodynamic therapy using Laserphyrin for centrally located early stage lung cancer" 2006
- ^ http://www.lsoncology.com/aptocine
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.